Genitourinary Cancers

Laurence Albiges, MD, PhD, discusses research evaluating treatments for subtypes of non–clear cell renal cell carcinoma.

Real-world treatment patterns demonstrated that similar OS outcomes occurred for patients with renal cell carcinoma who received TKI- and immunotherapy-based regimens.

Toni K. Choueiri, MD, discusses the phase 3 TiNivo-2 study in pretreated advanced renal cell carcinoma.

Neil J. Shah, MBBS, discusses unmet needs for patients with RCC receiving immune-oncology–based combinations in the frontline setting.

Sumanta Kumar Pal, MD, FASCO, discusses preliminary findings from a phase 1 dose-escalation study of DFF332 in patients with advanced ccRCC.

Using an AI tool for the collection and analysis of patient data may enhance the accuracy of outcome predictions and help personalize treatment plans.

Nivolumab plus ipilimumab may generate positive long-term outcomes in patients with advanced renal cell carcinoma regardless of IMDC risk status.

The FDA has granted fast track designation to ADI-270 for advanced clear cell renal cell carcinoma after an immune checkpoint inhibitor and VEGF inhibitor.

Vivek Subbiah, MD, discusses the rationale for combining sapanisertib with ziv-aflibercept in recurrent metastatic solid tumors, including kidney cancer.

Sumanta Kumar Pal, MD, FASCO, highlights key renal cell carcinoma research presented at the 2024 ASCO Annual Meeting, including early data with DFF332.

Vivek Subbiah, MD, details the rationale for combining sapanisertib with ziv-aflibercept or metformin and next steps for mTOR inhibitors in solid tumors.

Marijo Bilusic, MD, PhD, discusses the investigation of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors.

Joshua Linscott, MD, discusses using urinary cell-free tumor DNA to predict minimal residual disease in high-risk non-muscle invasive bladder cancer.

The EMA has validated an extension application for the subcutaneous formulation of nivolumab in adult patients with solid tumor indications.

Petros Grivas, MD, PhD, and Chandler H. Park, MD, FACP, discuss key updates in genitourinary cancer on OncLive News Network: On Location.

Benjamin L. Maughan, MD, PharmD, highlights ongoing research regarding the role of cytoreductive nephrectomy and targeted therapies in RCC.

Rohan Garje, MD, discusses the impact of human papillomavirus status on survival outcomes in penile squamous cell carcinoma.

Manmeet Ahluwalia, MD, MBA, FASCO, discusses findings from a National Cancer Database analysis on treatment outcomes of brain metastases from primary RCC.

David A. Braun, MD, PhD, highlights the developing role of T-cell therapies in RCC and looks toward the horizon for other advances.

Benjamin L. Maughan, MD, PharmD, dives into key studies in RCC regarding biomarkers and first-line treatments presented at the 2024 ASCO Annual Meeting

David A. Braun, MD, PhD, discusses the evolving treatment landscape of renal cell carcinoma.

Benjamin L. Maughan, MD, PharmD, discusses the implications of immuno-oncology and TKI agent combinations in clear cell and non–clear cell RCC.

Higher T-cell inflamed GEP values were positively associated with clinical outcomes for pembrolizumab plus axitinib in advanced clear cell RCC.

Lenvatinib/pembrolizumab offered a significant benefit in terms of time to disease progression in all organs vs sunitinib in advanced RCC.

Lenvatinib plus pembrolizumab displayed a superior clinical benefit vs sunitinib irrespective of patient biomarker subtype in advanced clear cell RCC.